Log in
Enquire now
‌

US Patent 9687485 Combination therapy with glutaminase inhibitors

Patent 9687485 was granted and assigned to Calithera Biosciences on June, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Calithera Biosciences
Calithera Biosciences
Current Assignee
Calithera Biosciences
Calithera Biosciences
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9687485
Patent Inventor Names
Dong Zhang0
Susanne M. Steggerda0
Mirna L. Rodriguez0
Andrew L. MacKinnon0
Francesco Parlati0
Date of Patent
June 27, 2017
Patent Application Number
14738279
Date Filed
June 12, 2015
Patent Primary Examiner
‌
James D. Anderson
Patent abstract

The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an anticancer agent such as an enzyme inhibitor (such as a kinase inhibitor), a mitotic inhibitor, a DNA-modifying agent, or a cytidine analog. The invention further relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases that are resistant to one or more anticancer agents.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9687485 Combination therapy with glutaminase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.